Ocugen, Inc. (OCGN)
| Market Cap | 252.71M -48.1% |
| Revenue (ttm) | 4.58M -3.6% |
| Net Income | -81.81M |
| EPS | -0.26 |
| Shares Out | 339.11M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,981,407 |
| Open | 0.7450 |
| Previous Close | 0.7247 |
| Day's Range | 0.7317 - 0.7899 |
| 52-Week Range | 0.6909 - 2.7250 |
| Beta | 1.98 |
| Analysts | Strong Buy |
| Price Target | 12.17 (+1,533.12%) |
| Earnings Date | Nov 4, 2026 |
About OCGN
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under ... [Read more]
Financial Performance
In 2025, Ocugen's revenue was $4.41 million, an increase of 8.83% compared to the previous year's $4.06 million. Losses were -$67.85 million, 25.5% more than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for OCGN stock is "Strong Buy." The 12-month stock price target is $12.17, which is an increase of 1,533.12% from the latest price.
News
Ocugen to Participate in Upcoming November Investor and Industry Conferences
MALVERN, Pa., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today announce...
Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4
MALVERN, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, will host a confere...
Ocugen executes licensing agreement with Roots Pharmaceutical
Ocugen (OCGN) announced the execution of a licensing agreement with Roots Pharmaceutical, and its strategic partner Al-Dhow International Holding, for the exclusive rights to OCU400, Ocugen’s novel mo...
Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
MALVERN, Pa., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the...
Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update
Calgary, Alberta--(Newsfile Corp. - October 7, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces that it has received full approval from the Nati...
Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate
MALVERN, Pa., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on developing and commercializing novel gene therapies to addre...
Ocugen Transcript: EGM 2026
The charter amendment to add 250 million authorized common shares lacked sufficient proxy support, so polls were not opened and the item was adjourned to October 26, 2026. The adjournment proposal had already passed; prior proxy votes remain valid unless revoked.
Ocugen to Participate in Upcoming Scientific Conferences
MALVERN, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today announc...
Ocugen to Participate in Upcoming October Investor and Industry Conferences
MALVERN, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today announc...
Ocugen’s OCU400 granted provisional approval, priority designation from LARTA
Ocugen (OCGN) announced that OCU400 has been granted provisional approval and priority designation from the LARTA Board, the regulatory agency responsible for reviewing and approving longevity and reg...
Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa
MALVERN, Pa., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced th...
Ocugen Transcript: EGM 2026
The meeting focused on increasing authorized shares and adjournment to solicit more proxies. The share increase proposal did not receive sufficient approval, so the meeting was adjourned to allow further voting, with the next session scheduled for October 5, 2026.
Ocugen Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Three late-stage gene therapy programs are advancing toward BLA submissions through 2028, with strong regulatory support and a focus on one-time treatments for major retinal diseases. Operational and commercialization plans prioritize U.S. launch, strategic partnerships abroad, and careful capital management to extend runway into 2028.
Ocugen price target lowered to $9.50 from $10 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Ocugen (OCGN) to $9.50 from $10 and keeps a Buy rating on the shares. The data monitoring committee provided “mixed messages” for…
Ocugen doses first patient in OCU410 trial
Ocugen (OCGN) announced that the first patient was dosed in the global Phase 3 registrational trial of OCU410, its modifier gene therapy candidate for GA secondary to dry age-related macular…
Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
MALVERN, Pa., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced th...
Ocugen to Participate in Upcoming September Investor and Industry Conferences
MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that th...
Ocugen Proxy statement: Proxy filing
Ocugen filed a proxy statement on August 14, 2026, providing details for shareholder voting and corporate governance matters.
Ocugen Transcript: Canaccord Genuity's 46th Annual Growth Conference
Late-stage gene therapy programs for blindness diseases are advancing, with pivotal data for RP and Stargardt expected in 2024 and potential global launches by 2028. The platform targets broad disease pathways, has strong safety data, and is supported by RMAT designation and extended financial runway.
Ocugen Earnings Call Transcript: Q2 2026
FDA cleared phase III for OCU410 in GA and granted RMAT designation; $130M financing extends cash runway into 2028. Three late-stage programs advance toward BLA filings by 2028, with top-line data for OCU400 and OCU410ST expected in H1 2027.
Ocugen Earnings release: Q2 2026
Ocugen released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Ocugen Quarterly report: Q2 2026
Ocugen has published its Q2 2026 quarterly earnings report on August 6, 2026.
Ocugen reports Q2 EPS (7c), consensus (5c)
Reports Q2 revenue $1.45M, consensus $888,830. “The second quarter of 2026 marked a pivotal inflection point for Ocugen (OCGN). We closed $130 million convertible senior notes financing, extending our...
Ocugen Provides Business Update with Second Quarter 2026 Financial Results
Conference Call and Webcast Today at 8:30 a.m. ET Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry age-related ...